Bullish indicating open at $55-$60, IPO prices at $37
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) stock soared to a 52-week high of $17.73, marking a significant milestone for the $2.07 billion market cap biopharmaceutical company. According to InvestingPro analysis, the company’s current valuation suggests it remains slightly undervalued. This peak reflects a robust year-over-year growth, with the stock experiencing an impressive 88.78% increase in value over the past year. The company’s fundamentals support this momentum, with remarkable revenue growth of 230% and industry-leading gross margins of 90%. Investors have shown increased confidence in Arcutis’ potential, driven by promising developments in the company’s pipeline and strategic partnerships. InvestingPro data reveals 12 additional key insights available for subscribers. The 52-week high serves as a testament to the company’s solid performance and the market’s optimistic outlook on its future prospects, further supported by a healthy current ratio of 4.15, indicating strong short-term financial stability.
In other recent news, Arcutis Biotherapeutics Inc. reported its fourth-quarter 2024 earnings, showcasing a significant earnings per share (EPS) beat with an EPS of -$0.09, surpassing the expected -$0.28. The company’s revenue for the quarter reached $71.3 million, exceeding the anticipated $54.72 million, marking a 413% year-over-year increase. Mizuho (NYSE:MFG) Securities responded by raising Arcutis’ stock price target to $21.00 from $20.00, maintaining an Outperform rating due to the company’s better-than-expected earnings and robust sales of its Zoryve franchise, which brought in $69.4 million. Jefferies also expressed confidence in Arcutis, raising its price target to $19.00 while retaining a Buy rating, citing the promising market performance of the company’s product Zoryve. Additionally, the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application for ZORYVE cream 0.05% for young children with atopic dermatitis, setting a review date for October 2025. This potential approval could expand treatment options for children aged 2 to 5, supported by positive trial results. Arcutis’ management has expressed optimism about future sales growth, with a new forecast for the Zoryve franchise’s 2025 sales increased to approximately $299 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.